Short-Term Efficacy and Safety of Secukinumab for Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of RCTs
Secukinumab is a novel IL-17A inhibitor that has been confirmed to be effective for treating PsA and RA. Several studies have demonstrated that secukinumab also provides benefits for AS patients. Thus, we performed a meta-analysis of RCTs to evaluate the short-term efficacy and safety of secukinumab...
Saved in:
Main Authors: | Yu Zhou (Author), Jinhui Ma (Author), Juncheng Ge (Author), Bailiang Wang (Author), Debo Yue (Author), Weiguo Wang (Author) |
---|---|
Format: | Book |
Published: |
Hindawi Limited,
2020-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Secukinumab for ankylosing spondylitis and psoriatic arthritis
by: Lubrano E, et al.
Published: (2016) -
Effectiveness of secukinumab for overlapping hidradenitis suppurativa and ankylosing spondylitis
by: Mariam AlAfeefi, et al.
Published: (2024) -
Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis
by: Elena Conesa-Nicolás, et al.
Published: (2021) -
Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis
by: Elalouf O, et al.
Published: (2015) -
Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland
by: Purmonen T, et al.
Published: (2019)